Expression levels of miR-34a, miR-150, and miR-923 in cancerous and non-malignant sample groups in the validation cohort and independent data set. (A) Cancer samples show significantly higher miR-34a expression (p-value < 0.001) compared to non-malignant samples in both the validation plasma samples and independent tumour tissue samples. (B) Cancer samples show significantly lower miR-150 expression compared to non-malignant samples in both the validation plasma samples (p-value =0.003) and independent tumour tissue samples (p-value < 0.001). (C) No significant change in miR-923 expression is observed in either the validation plasma samples (p-value = 0.56) or the independent tumour tissue samples (p-value = 0.35). The non-malignant group in the validation cohort represents the normal, polyp, and adenoma samples. Cancer groups in both studies represent cancers of all stages I-IV. Expression levels of the miRNAs (log10 scale at y-axis) are normalised to let-7e in the validation cohort and mean normalised in the independent dataset. Statistically significant differences between groups were determined using Wilcoxon rank sum tests in both the validation and independent cohorts.